DarioHealth (NSDQ:DRIO) said today that it inked a deal with an unnamed pharmaceutical company to combine its blood glucose monitoring tech into the company’s clinical trial.
The Israel-based device-maker reported that this pharmaceutical company is conducting a trial of its diabetes drug that will eventually be included in a regulatory package for FDA approval.
Get the full story at our sister site, Drug Delivery Business News.
The post DarioHealth inks deal to use blood glucose tech in pharma company’s clinical trial appeared first on MassDevice.